Introduction {#Sec1}
============

The characteristic features of children and adolescents with attention deficit hyperactivity disorder (ADHD) are excessive motor activity, inattention and impulsiveness (e.g. Lange et al. [@CR30]; Tucha et al. [@CR39], [@CR40]). The treatment with psychostimulants such as methylphenidate is the standard pharmacological therapy of ADHD (e.g. Lange et al. [@CR29]; Tucha et al. [@CR36], [@CR37], [@CR38]). Methylphenidate has been shown to increase dopaminergic and noradrenergic activity most likely by blocking noradrenaline and dopamine transporters (Heal et al. [@CR23]). These neurotransmitters appear, therefore, to play an important role in ADHD. However, it is not fully understood how an increase in catecholaminergic activity ameliorates the symptoms of ADHD. The degeneration of the locus coeruleus (LC), which is the main source of noradrenaline in the central nervous system, has been associated with deficits in attention and selective processing of sensory stimuli (Coull [@CR13]). An increase in noradrenaline leads to a more focused behaviour whereas a decrease in noradrenaline increases the reaction to irrelevant stimuli (Aston-Jones et al. [@CR5]). These observations suggest that a decrease in central noradrenaline might contribute to ADHD. Since there is a similarity in symptoms between patients with ADHD and those with prefrontal lesions (Benton [@CR7]; Heilman et al. [@CR24]; Levin [@CR31]; Mattes [@CR32]) it has been postulated that the prefrontal cortex (PFC) is critically involved in ADHD. This view is underlined by the fact that abnormalities within the prefrontal cortex have been found in children with ADHD (Castellanos et al. [@CR9]; Filipek et al. [@CR17]; Hynd et al. [@CR28]). The prevailing theory regarding the neurobiology of ADHD suggests an imbalance of dopamine and noradrenaline in the prefrontal cortex (Arnsten [@CR1], [@CR2]; Himelstein et al. [@CR26]). In summary, these findings suggest that a reduction in noradrenaline can induce prefrontal deficits which might contribute to ADHD.

In the present experiment, a depletion of central noradrenaline was induced with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). This neurotoxin is known to selectively destroy the terminals of the LC (Fritschy and Grzanna [@CR20]) and to reduce the noradrenergic activity in a dose-dependent manner (Cheetham et al. [@CR10]). We have used different doses of DSP4 to induce different imbalances between dopamine and noradrenaline and expected to find behavioural deficits related to the prefrontal cortex. In order to assess prefrontal functions such as working memory, we have used a holeboard task where rats are required to find hidden food pellets (Heim et al. [@CR25]). Different doses of methylphenidate (MPH) were used in order to treat the expected deficits.

Materials and methods {#Sec2}
=====================

Animals and feeding procedure {#Sec3}
-----------------------------

Forty-eight male Wistar rats aged about 3 months (weight approximately 230 g at the beginning of the experiment) were used. The animals were kept on a 12:12 h light--dark cycle (room temperature 21°C, humidity 55%). Water was provided ad libitum.

All experiments were performed in accordance with the national laws (German law on Protection of Animals) and the principles of laboratory animal care (NIH publication No. 86-23, revised 1985).

Training, DSP4 administration and test procedure {#Sec4}
------------------------------------------------

Prior to the administration of the neurotoxin DSP4, the rats were trained once a day on the COGITAT System until each rat had found the hidden pellets at least twice. This training period lasted approximately 3 weeks. The animals were trained in the morning and the order in which the rats were trained on the board was balanced. When the animals had reached this level, they were divided in four groups of 12 animals each. The rats in the four groups were matched according to number of pellets eaten, working memory error and reference memory error.

The animals of the control group were injected with saline (DSP4_C); the animals of the other three groups received an injection of DSP4 (Sigma-Aldrich, Schnelldorf, Germany) at a dose of 10 mg/kg (DSP4_1), 20 mg/kg (DSP4_2), or 50 mg/kg (DSP4_3). Both DSP4 and saline were administered intraperitoneally. Following the injections, the animals were not tested for 2 weeks in order to allow for a recovery of the peripheral noradrenergic system (Fritschy and Grzanna [@CR20]). The feeding of the animals was kept constant during this period. The animals were then tested again with the same pellet pattern on the COGITAT System (10 trials per rat over 2 weeks). The rats were put on starvation rations during the week prior to testing with the COGITAT System and throughout the subsequent test periods. The rats' weight was carefully controlled and a weight reduction of more than 10--15% was avoided in order to prevent stress (Bear [@CR6]; Deroche et al. [@CR14]) and subsequent changes in the dopaminergic system (Pothos et al. [@CR33]). The rats were fed 1 h prior to the start of testing. This procedure was chosen for two reasons: (1) rats awaiting their daily feeding after testing may not search properly during the trials; (2) feeding shortly before testing avoids the decrease in dopamine release associated with chronic food deprivation (Pothos et al. [@CR33]).

Injection of MPH {#Sec5}
----------------

The effects of MPH were tested using three different doses of the drug and saline as control (2.5, 5, 10 mg/kg). These doses have been shown to improve attentional functions as assessed with the 5-choice-serial-reaction-time task (Bizarro et al. [@CR8]). The injections were given 10 min before the testing because the maximum concentration in the brain can be measured within the first 20 min after administration (Huff and Davies [@CR27]). Each rat was tested with saline and the three MPH doses. Saline and each MPH dose were injected over five consecutive days. In order to avoid carry-over effects, the order in which the rats were injected was balanced using Latin squares. A wash-out period of 3 days was used (Yang et al. [@CR41]).

COGITAT Hole Board {#Sec6}
------------------

The learning behaviour of the rats was tested with the COGITAT Hole Board System (Cogitron GmbH, Göttingen, Germany). This system consists of a board with 25 holes (Fig. [1](#Fig1){ref-type="fig"}). Each hole of the board is closed at its lower end by an adjustable feeding plate with a depression for a food pellet. Feeding plate and food pellets are of the same colour. The ground below the feeding plate is covered with the same pellets as those used in the cylindrical tubes, in order to prevent the animals from finding the pattern of the pellet distribution by using olfactory stimuli. Each hole is fitted with infra-red light beams at different levels of the hole to measure activity. Finally, there is an infra-red beam at the feeding plate measuring the collection of a food pellet. A more detailed description of the COGITAT Hole Board System can be found elsewhere (Heim et al. [@CR25]).Fig. 1Schematic drawing of the COGITAT system

In the present experiment, eight of the 25 holes were baited (Fig. [1](#Fig1){ref-type="fig"}). A search trial was automatically finished when a rat had found all the hidden pellets or after a fixed period of time (60 s).

In each single trial, the following parameters were measured: (1) working memory error (i.e. the percentage of inspections to previously baited holes in a single trial in relation to the total number of holes inspected); (2) reference memory error (i.e. the percentage of inspections to non-baited holes in relation to the total number of holes inspected); (3) pellets eaten (the number of pellets eaten); (4) inspections (i.e. the number of interruptions of the upper light beam only).

In addition, all trials were recorded with a video system. This data was digitalised and analysed using the video tracking system ETHOVISION 3.0 (Noldus, Wageningen, The Netherlands). The parameter measured was the route covered, i.e. the distance travelled by the rats (per trial, in cm).

Statistics {#Sec7}
----------

Statistical analyses were performed using the non-parametric Wilcoxon-test, an alpha level of 0.05 was applied. The analyses were performed using the Statistical Package for Social Sciences 13.0 (SPSS) for Windows.

Results {#Sec8}
=======

In the following, the calculated values are given as means ± standard error of the means.

Pellets eaten (Fig. [2](#Fig2){ref-type="fig"}) {#Sec9}
-----------------------------------------------

### Comparison between the DSP4 groups after saline injection {#Sec10}

The DSP4 groups differed in the saline condition, whereas the DSP4_C group found significantly more pellets compared to the DSP4_1 (7.74 ± 0.18 vs. 6.93 ± 0.59; *P* ≤ 0.01) and the DSP4_3 (7.74 ± 0.18 vs. 6.52 ± 0.69; *P* ≤ 0.01). The DSP4_2 group found more pellets than the DSP4_1 group (7.52 ± 0.31 vs. 6.93 ± 0.59; *P* ≤ 0.05) and the DSP4_3 group (7.52 ± 0.31 vs. 6.52 ± 0.69; *P* ≤ 0.05).Fig. 2Number of pellets eaten (*error bars* indicate SEM)

### Treatment with MPH in the DSP4_C group {#Sec11}

The treatment of the rats in the DSP4_C group with MPH at a dose of 2.5 mg/kg induced a small but significant increase in pellets found in comparison with the saline injection (saline vs. MPH 2.5 mg: 7.74 ± 0.18 vs. 7.93 ± 0.09; *P* ≤ 0.05). Treating this group with 10 mg/kg of MPH decreased the number of pellets eaten compared to the treatment with 2.5 mg MPH (MPH 2.5 mg vs. MPH 10 mg: 7.93 ± 0.09 vs. 7.53 ± 0.33; *P* ≤ 0.05).

### Treatment with MPH in the DSP4_1 group (10 mg/kg DSP4) {#Sec12}

The treatment of the DSP4_1 group with MPH had no statistically significant effects on the number of pellets eaten in comparison with the saline injection.

### Treatment with MPH in the DSP4_2 group (20 mg/kg DSP4) {#Sec13}

The treatment of the DSP4_2 group with the high dose of MPH (10 mg/kg) resulted in a significant decrease in the number of pellets eaten in comparison with the saline injection (saline vs. MPH 10 mg: 7.52 ± 0.31 vs. 5.82 ± 0.90; *P* ≤ 0.01). The treatment with 2.5 mg/kg of MPH also induced a reduction in the number of pellets eaten (saline vs. MPH 2.5 mg: 7.52 ± 0.31 vs. 6.46 ± 0.70; *P* ≤ 0.05).

### Treatment with MPH in the DSP4_3 group (50 mg/kg DSP4) {#Sec14}

The treatment of the DSP_3 group with 5 mg/kg of MPH induced a significant decrease in the number of pellets eaten in comparison with the saline injection (saline vs. MPH 5 mg: 6.52 ± 0.69 vs. 4.67 ± 0.95; *P* ≤ 0.01). The low dose of MPH also reduced this number (saline vs. MPH 2.5 mg: 6.52 ± 0.69 vs. 5.41 ± 0.86; *P* ≤ 0.05). The high dose of MPH had no statistically significant effect on the number of pellets eaten.

Working memory error (Fig. [3](#Fig3){ref-type="fig"}) {#Sec15}
------------------------------------------------------

### Comparison between the DSP4 groups after saline injection {#Sec16}

There were no significant differences between the groups. However, the highest dose of DSP4 induced an increase in the working memory error.Fig. 3Working memory error (*error bars* indicate SEM)

### Treatment with MPH in the DSP4_C group {#Sec17}

No significant differences between the three doses of MPH and saline injection were found.

### Treatment with MPH in the DSP4_1 group (10 mg/kg DSP4) {#Sec18}

No significant differences between the three doses of MPH and saline injection were found.

### Treatment with MPH in the DSP4_2 group (20 mg/kg DSP4) {#Sec19}

A significant difference was found between the doses of 2.5 and 5 mg/kg of MPH (MPH 2.5 mg vs. MPH 5 mg: 13.95 ± 7. vs. 26.81 ± 10.43; *P* ≤ 0.05). No other significant differences were found.

### Treatment with MPH in the DSP4_3 group (50 mg/kg DSP4) {#Sec20}

No significant differences between the three doses of MPH and saline injection were found.

Inspections (Fig. [4](#Fig4){ref-type="fig"}) {#Sec21}
---------------------------------------------

### Comparison between the DSP4 groups after saline injection {#Sec22}

There are no significant differences.Fig. 4Number of inspections of holes (*error bars* indicate SEM)

### Treatment with MPH in the DSP4_C group {#Sec23}

MPH at a dose of 2.5 or 5 mg/kg had no significant effect on the number of inspections compared to saline. However, the dose of 10 mg/kg significantly increased the inspection rate compared to saline (saline vs. MPH 10 mg: 1.81 ± 1.56 vs. 6.10 ± 3.16; *P* ≤ 0.01).

### Treatment with MPH in the DSP4_1 group (10 mg/kg DSP4) {#Sec24}

The treatment with MPH increased the number of inspections in this group in a dose-dependent manner. In comparison to the saline injection, the increase in inspections was significant for the MPH doses of 2.5 mg/kg (saline vs. MPH 2.5 mg: 1.25 ± 0.54 vs. 5.45 ± 2.20; *P* ≤ 0.01), 5 mg/kg (saline vs. MPH 5 mg: 1.25 ± 0.54 vs. 6.13 ± 2.02; *P* ≤ 0.01) and 10 mg/kg (saline vs. MPH 10 mg: 1.25 ± 0.54 vs. 8.02 ± 2.81; *P* ≤ 0.01).

### Treatment with MPH in the DSP4_2 group (20 mg/kg DSP4) {#Sec25}

The treatment with all three doses of MPH significantly increased the number of inspections compared to the saline injection: with 2.5 mg/kg (saline vs. MPH 2.5 mg: 1.83 ± 0.81 vs. 4.66 ± 1.68; *P* ≤ 0.05), with 5 mg/kg (saline vs. MPH 5 mg: 1.83 ± 0.81 vs. 5.54 ± 2.54; *P* ≤ 0.05) and with 10 mg/kg (saline vs. MPH 10 mg: 1.83 ± 0.81 vs. 8.36 ± 2.54; *P* ≤ 0.05).

### Treatment with MPH in the DSP4_3 group (50 mg/kg DSP4) {#Sec26}

The treatment with all three doses of MPH significantly increased the number of inspections compared to the saline injection: (saline vs. MPH 2.5 mg: 2.13 ± 1.36 vs. 6.47 ± 1.73; *P* ≤ 0.01), (saline vs. MPH 5 mg: 2.13 ± 1.36 vs. 7.52 ± 1.82; *P* ≤ 0.01) and (saline vs. MPH 10 mg: 2.13 ± 1.36 vs. 9.17 ± 2.52; *P* ≤ 0.01).

Reference memory error (Fig. [5](#Fig5){ref-type="fig"}) {#Sec27}
--------------------------------------------------------

### Comparison between the DSP4 groups after saline injection {#Sec28}

The treatment with saline did not have any effect on this parameter in the DSP4 treated groups.Fig. 5Reference memory error (*error bars* indicate SEM)

### Treatment with MPH in the DSP4_C group {#Sec29}

The treatment with 10 mg/kg of MPH induced a significant increase in the reference memory error compared to saline injection (saline vs. MPH 10 mg: 15.98 ± 9.55 vs. 38.42 ± 11.43; *P* ≤ 0.01) and to the dose of 2.5 mg/kg of MPH (MPH 2.5 mg vs. MPH 10 mg: 22.85 ± 10.80 vs. 38.42 ± 11.43; *P* ≤ 0.05).

### Treatment with MPH in the DSP4_1 group (10 mg/kg DSP4) {#Sec30}

The treatment with 10 mg/kg of MPH induced a significant increase in the reference memory error compared to saline injection (saline vs. MPH 10 mg: 18.56 ± 10.08 vs. 31.83 ± 10.36; *P* ≤ 0.05).

### Treatment with MPH in the DSP4_2 group (20 mg/kg DSP4) {#Sec31}

The treatment of the DSP4_2 group with MPH at doses of 2.5 and 10 mg/kg increased the reference memory error compared to the saline injection (saline vs. MPH 2.5 mg: 16.62 ± 8.55 vs. 29.98 ± 9.80; *P* ≤ 0.05), (saline vs. MPH 10 mg: 16.62 ± 8.55 vs. 27.42 ± 8.82; *P* ≤ 0.05).

### Treatment with MPH in the DSP4_3 group (50 mg/kg DSP4) {#Sec32}

The treatment with all three doses of MPH significantly increased the reference memory error compared to the saline injection (saline vs. MPH 2.5 mg: 17.45 ± 10.07 vs. 41.37 ± 9.65; *P* ≤ 0.01), (saline vs. MPH 5 mg: 17.45 ± 10.07 vs. 38.83 ± 7.44; p ≤ 0.01), (saline vs. MPH 10 mg: 17.45 ± 10.07 vs. 43.97 ± 8.78; *P* ≤ 0.01).

Route covered (Fig. [6](#Fig6){ref-type="fig"}) {#Sec33}
-----------------------------------------------

### Comparison between the DSP4 groups after saline injection {#Sec34}

There was no significant difference between the groups.Fig. 6Route covered (*error bars* indicate SEM)

### Treatment with MPH in the DSP4_C group {#Sec35}

The high dose of MPH induced an increase in the route covered (saline vs. MPH 10 mg: 193.75 ± 55.93 vs. 320.84 ± 92.62; *P* ≤ 0.01).

### Treatment with MPH in the DSP4_1 group (10 mg/kg DSP4) {#Sec36}

All MPH doses increased the route covered in comparison with the saline injection (saline vs. MPH 2.5 mg: 193.50 ± 55.86 vs. 328.57 ± 94.85; *P* ≤ 0.01), (saline vs. MPH 5 mg: 193.50 ± 55.86 vs. 364.05 ± 105.09; *P* ≤ 0.01), (saline vs. MPH 10 mg: 193.50 ± 55.86 vs. 416.56 ± 120.25; *P* ≤ 0.01).

### Treatment with MPH in the DSP4_2 group (20 mg/kg DSP4) {#Sec37}

All MPH doses increased the route covered in comparison with the saline injection (saline vs. MPH 2.5 mg: 205.87 ± 59.43 vs. 320.41 ± 92.50; *P* ≤ 0.01), (saline vs. MPH 5 mg: 205.87 ± 59.43 vs. 368.54 ± 106.39; *P* ≤ 0.05), (saline vs. MPH 10 mg: 205.87 ± 59.43 vs. 445.87 ± 128.71; *P* ≤ 0.01).

### Treatment with MPH in the DSP4_3 group (50 mg/kg DSP4) {#Sec38}

All MPH doses increased the route covered in comparison with the saline injection (saline vs. MPH 2.5 mg: 187.17 ± 54.03 vs. 367.36 ± 106.05; *P* ≤ 0.01), (saline vs. MPH 5 mg: 187.17 ± 54.03 vs. 482.40 ± 139.26; *P* ≤ 0.01), (saline vs. MPH 10 mg: 187.17 ± 54.03 vs. 490.70 ± 141.65; *P* ≤ 0.01).

Discussion {#Sec39}
==========

The present experiment was performed in order to investigate the effects of noradrenaline depletion on cognition in rats and the administration of MPH. Given the role of the LC in the regulation of attention processes, we expected to find impaired cognition due to the administration of DSP4.

The animal groups treated with three different doses of DSP4 differed significantly in the number of pellets eaten. The rats treated with the low and the high doses of DSP4 ate the lowest number of pellets compared to the saline group (Fig. [2](#Fig2){ref-type="fig"}). Similar differences were also observed in our previous experiment (Sontag et al. [@CR34]) indicating cognitive difficulties in the DSP4-treated rats. The LC neurons project, among others, to the prefrontal cortex and show two distinct firing modes, i.e. (1) tonic firing which is associated with arousal, sensory information processing, attention, working memory and motor processes (Arnsten and Dudley [@CR3]; Aston-Jones et al. [@CR4]; Devilbiss and Waterhouse [@CR16]; Foote et al. [@CR18], [@CR19]) and (2) phasic discharge which is associated with alerting and orienting reactions, sustained attention and decision-making (Aston-Jones et al. [@CR4]; Clayton et al. [@CR12]). We therefore expected to find deficits in working memory. With increasing doses of DSP4 a non-significant increase in working memory error was found (Fig. [3](#Fig3){ref-type="fig"}). No increase was found for the reference memory error (Fig. [5](#Fig5){ref-type="fig"}). This suggests that DSP4 induces deficits in working memory rather than in reference memory.

The administration of MPH induced only minor effects. There was a small but significant increase in the number of pellets eaten following the administration of 2.5 mg/kg MPH. The working memory error decreased, though not significantly, following treatment with 2.5 mg/kg of MPH, indicating an improvement in cognition. However, with increasing doses both the reference and the working memory error increased, suggesting a decline in cognitive functions (Figs. [3](#Fig3){ref-type="fig"}, [5](#Fig5){ref-type="fig"}) An impairment of working memory with increasing doses of MPH was also reported by Devilbiss and Berridge ([@CR15]) who showed that MPH at a dose of 2.0 mg/kg induces severe deficits in working memory whereas a dose below 2.0 mg/kg enhances working memory in naïve rats. It was also reported that the administration of 2.5 mg/kg MPH induced a significant increase in motor activity (Gaytan et al. [@CR22]) and the use of small MPH doses was suggested by Arnsten and Dudley ([@CR3]) in order to avoid the stimulating effects on motor activity. However, the rats in the present study did not walk longer distances after 2.5 or 5 mg/kg of MPH (Fig. [6](#Fig6){ref-type="fig"}). Only the high dose of MPH increased the distances walked by the rats. The effect on working memory was minor compared to the data presented by Devilbiss and Berridge ([@CR15]). Both Devilbiss and Berridge ([@CR15]) and Gaytan et al. ([@CR22]) used Sprague--Dawley rats whereas we used Wistar rats. The present results may therefore suggest a reduced sensitivity to the effects of MPH in Wistar rats. Furthermore, it can be excluded that the alterations in cognitive functions found in the DSP4-C group after the injection of 2.5 or 5 mg/kg MPH are related to an increase in motor activity.

The pre-treatment with DSP4 appears to potentiate the effects of MPH. The treatment of the DSP4_3 group with 2.5 mg/kg MPH significantly increased the reference memory error which did not further increase with higher doses of MPH. This finding suggests a ceiling effect (Fig. [5](#Fig5){ref-type="fig"}). The increase in reference memory error was associated with a decrease in the number of pellets eaten (Fig. [2](#Fig2){ref-type="fig"}). These findings indicate a deficit in spatial memory induced by MPH. This is underlined by the fact that the rats travelled significantly longer distances during the testing (Fig. [6](#Fig6){ref-type="fig"}). The dose of 2.5 mg/kg MPH had no such effects on the DSP4-C group, on the contrary, this dose slightly increased the cognition in the rats. An increase in the reference memory error, a decrease in the pellets eaten, and an increase in the distance travelled were, though less pronounced, also observed in the DSP4_2 group (Figs. [2](#Fig2){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}). By contrast, the DSP4_1 group showed only a significant increase in the reference memory error after the high dose of MPH (Fig. [5](#Fig5){ref-type="fig"}). These findings suggest that the pre-treatment with different doses of DSP4 induced different sensitivities to MPH, leading to deficits in spatial reference memory.

It was expected that MPH would reduce working memory deficits in DSP4-treated rats. Since MPH increases noradrenaline release, it was also expected that this effect would be more pronounced in the groups treated with the low doses of DSP4 because more noradrenergic LC terminals would survive this treatment (Cheetham et al. [@CR10]). However, no significant effects of MPH on working memory compared to saline were found in any of the DSP4-treated groups. The effects of MPH and DSP4 on reference memory and the lack of effects on working memory suggest that the MPH and DSP4 might have affected brain structures outside the prefrontal cortex, most likely the hippocampus.

Both prefrontal cortex and hippocampus receive innervations from the LC (Foote et al. [@CR19]). The administration of DSP4 may therefore have depleted noradrenaline in both brain regions. For the hippocampus, Chrobak et al. ([@CR11]) reported a significant decrease of noradrenaline but no effect on dopamine following the administration of DSP4 in rats. This study also showed that the administration of DSP4 did not affect spatial memory. Another study has shown that a decrease in dopamine disturbs spatial learning (Gasbarri et al. [@CR21]). MPH increases both dopamine and noradrenaline release. In DSP4-treated rats, however, noradrenaline release is markedly reduced since DSP4 destroys the noradrenergic terminals. One would therefore expect that MPH increased dopamine release in the hippocampus. This reasoning is in contrast to the finding that a decrease in hippocampal dopamine disturbs spatial learning (Gasbarri et al. [@CR21]).

Another possibility is that the increase in reference memory error in DSP4-treated rats after MPH administration is related to an increase in motor activity. We found no stimulation of motor behaviour in saline-treated rats but in all DSP4 pre-treated rats MPH induced a significant increase in motor activity (Fig. [6](#Fig6){ref-type="fig"}) Furthermore, MPH also increased the number of inspections, indicating an increase in impulsive behaviour (Fig. [4](#Fig4){ref-type="fig"}). This suggests that a reduction of noradrenaline in combination with an increase in dopamine induce motor hyperactivity and impulsivity, two core symptoms of ADHD.

In summary, central noradrenaline depletion following DSP4 administration induced cognitive deficits without affecting reference memory. The treatment with MPH affected reference memory rather than working memory. In addition, there were indications that MPH also increased impulsivity and motor activity of the DSP4-treated rats, which are two core symptoms of ADHD. Since the noradrenergic terminals in a DSP4-treated rat are significantly reduced, the administration of MPH increases dopaminergic activity rather than noradrenergic activity. These results therefore suggest that a reduction of noradrenaline and an increase of dopamine may induce ADHD-related deficits. The sole depletion of noradrenaline is therefore not sufficient for an appropriate rat model of ADHD (see Sontag et al. [@CR35]).
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